



Contra Costa Health Plan
P&T Formulary Update
December 2, 2021

Changes effective: 1/15/2021

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On December 2, 2021 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Anti-obesity medications • Pneumonia vaccines • Topical agents for Actinic Keratosis	• Ketone test strips • Androgens • Multi-vitamins with fluoride • Fluoride dental preps
Drug Monographs	
• Methergine	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Botox • Wakix (pitolisant) • Sleep disorder Therapy ○ Sunosi (solriamfetol) ○ Xyrem (sodium oxybate) ○ Xywav (calcium, magnesium, potassium, and sodium oxybates) • Wegovy (semaglutide) • Lomaira (phentermine) <u>Updates were made to the criteria for the following agents:</u> • Pediculides: Malathion, Sklice, Spinosad • Icosapent Ethyl (Vascepa) • Growth Hormone: Skytrofa (Ionapegmatropin) • Topical Vitamin D analogs: Taclonex ointment, Sorilux (calcipotriene) foam • Apremilast (Otezla) • Urinary antispasmodics: Vesicare LS (solifenacin) 1mg/ml suspension, Myrbetriq (mirabegron) 8mg/ml oral suspension, Gemtesa (vibegron) 75mg tablet <u>Criteria reviewed and unchanged:</u>	

- Ketone test strips
- Androgens
- Multi-vitamins with fluoride
- Fluoride dental preps
- Allopurinol (Aloprim) 500mg IV solution

Updates to the CCHP formulary were made for the following agents:

- Solifenacin
- Colchicine
- Crotan (crotamiton) 10% lotion
- Fluorouracil (Carac) 0.5% topical cream
- Fluoroplex (fluorouracil) 1% topical cream

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Solifenacin (Vesicare) 5mg, 10mg	Added to formulary, Tier 1
Colchicine (Colcrys) 0.6mg tablet	Added to formulary, Tier 2 increased QL
Prevnam 20 IM syringe	Added to formulary, Tier 2 QL added
Vaxneuvance 0.5ml IM syringe	Added to formulary, Tier 2 QL added
Xyrem 500mg/ml oral solution	Removed from formulary
Allopurinol (Aloprim) 500mg IV soln	Removed from formulary
Fluorouracil (Carac) 0.5% topical cream	Removed from formulary
Fluoroplex (Fluorouracil) 1% topical cream	Removed from formulary
Methitest (methyltestosterone) 10mg tablet	Removed from formulary
Oxandrolone (Oxandrin) 2.5mg, 10mg tablets	Removed from formulary

New Product Reviews (including new indications)

- | | |
|--|--|
| <ul style="list-style-type: none"> • Bylvay (odevixibat) oral pellet, capsule • Rezurock (belumosudil mesylate) tablet • Saphnelo (anifrolumab-fnia) 300mg/2ml IV • Nexvazyme (avalglucosidase alfa-ngpt) 100mg IV solution • Hexatrione (triamcinolone) 20mg/ml susp. • Vaxneuvance (pneumococcal 15-val) • Welireg (Belzutifan) 40mg tablet • Trudhesa (Dihydroergotamine) nasal spray • Lybalvi (olanzapine/samidorphan) tablet • Exkivity (mobocertinib) 40mg capsule • Opzelura (ruxolitinib) 1.5% topical cream | <ul style="list-style-type: none"> • Thalitone (chlorthalidone) 15mg tablet • Qulipta (atogepant) tablet • Skytrofa (lonapegsom atropine-tcgd) SubQ • Tavneos (avacopan) 10mg capsule • Tyrvaya (Varenicline) nasal spray • Rethymic (thymus tissue-a gdc) • Susvimo (ranibizumab) 10mg/0.1ml implant |
|--|--|